3D Printed Drugs Market Projected to Surge to USD 742.88 Million by 2032 at a 9.2% of CAGR

Posted on 2024-08-22 by Future Market Insights in Healthcare, Pharmaceuticals // 0 Comments

3D Printed Drugs Market

The global 3D printed drugs market is set for significant growth, with an estimated market value of USD 307.54 million in 2022. Projections indicate the market will reach approximately USD 742.88 million by 2032, reflecting a robust compound annual growth rate (CAGR) of 9.2% over the forecast period.

This growth is largely driven by the rising demand for personalized pharmaceuticals across various age groups. 3D printing technology enables the creation of customized drug formulations tailored to individual patient needs, enhancing treatment efficacy and patient satisfaction.

As advancements in 3D printing technology continue to evolve, the pharmaceutical industry is poised to benefit from increased flexibility and innovation in drug development and manufacturing. The expanding capabilities of 3D printing are expected to revolutionize how medications are produced and delivered, further fueling market expansion.

Quick solubility and customizable aspect of 3D printed drugs augments the demand for the same in the international market. These drugs are produced by the help of powder bed inkjet printing by adding the drug’s components in a layer by layer format- similar to 3D printing for any other application. This process of production makes the medications easier to swallow and is advantageous for people suffering from dysphagia.

Moreover, 3D printing has the potential to fasten up the arrival of customized pharmaceuticals or the development of therapeutic blends. With the help of 3D printing, medications could be personalized for each patient, which will likely be more effective than batch-produced medications as they would be produced individually with consideration for that patient’s medical history. All of these considerations aid the growth of the 3D printed drugs market during the forecast period.

“A surge in the demand for customized medications will fuel the global growth of the 3D printed drugs market over the forecast period,” says an FMI analyst.

Key Takeaways:

The inkjet printer technology segment will hold 24% of the 3D printed drugs market share by the end of 2022.
The hospitals and clinics end-user segment will own about 45% of the overall market share.
In 2022, the 3D printed drugs market in North America will account for 31.1% of the total market share.
Europe’s 3D drug printing market will hold 29.9% of the market share in 2022.
Immense potential for 3D printed drugs research will drive the Asia Pacific market to hold 27% of the overall market share in 2022.

Competitive Landscape:

Hewlett Packard Caribe, Merck, Cycle Pharmaceuticals, AstraZeneca, Aprecia, Osmotica Pharmaceuticals, Aprecia Pharmaceuticals LLC Extend Biosciences, Bioduro, Affinity Therapeutics, GlaxoSmithKline Plc, and FabRx Ltd. among others are some of the major players in the 3D printed drugs market profiled in the full version of the report.

Key market players are focusing on product development and new product launches to meet the growing demand. These organizations also employ strategic partnership and collaboration tactics to gain a competitive advantage.

More Insights into 3D Printed Drugs Market Report

In its latest report, FMI offers an unbiased analysis of the global 3D printed drugs market, providing historical data from 2017 to 2021 and forecast statistics for 2022 to 2032. To understand the global market potential, growth, and scope, the market is segmented on the basis of the dosage form (3D printed tablets, 3D printed capsules, 3D printed multi drug implants, 3D printed nanoparticles, 3D printed solutions, other 3D printed drug dosage forms), technology (inkjet 3D printed drugs, direct write 3D printed drugs, zip dose 3D printed drugs, thermal inkjet 3D printed drugs, 3D printed drugs based on fuel deposition modeling, powder bed 3D printed drugs, stereo lithography (SLA) 3D printed drugs, semi solid extrusion (SSE) 3D printed drugs), and region.

According to the latest FMI reports, based on segmentation, the inkjet printer technology will gain momentum over the forecast period. This segment will likely account for 24% of the 3D printed drugs market share in 2022. Owing to technological advancement the inkjet printers are easier and convenient to use. In terms of end use, hospitals and clinics are expected to be major contributors to the overall growth of the target market As easy installation and fewer waste fasten up the manufacture of 3D printed drugs in hospitals and clinics, these end users are predicted to hold 45% of the overall market share.

Based on region, the 3D printed drugs market in North America will exhibit impressive growth during 2022-2032. Increasing incidences of chronic diseases, an aging population, access to a well-established healthcare infrastructure are some of the factors that drive the target market in this region. Thus, the 3D printed drugs market in North America will account for 31.1% of the total market share in 2022. Besides North America, Europe and the Asia Pacific regions, too, will register considerable 3D printed drugs market growth during the forecast period.

Key Companies Profiled

Hewlett Packard Caribe
Merck
Cycle Pharmaceuticals
AstraZeneca
Aprecia
Osmotica Pharmaceuticals
Aprecia Pharmaceuticals LLC
Extend Biosciences
Bioduro
Affinity Therapeutics
GlaxoSmithKline Plc
FabRx Ltd

A Old Full Report Analysis Click Here

Key Segments Covered in the 3D Printed Drugs Industry Analysis

3D Printed Drugs Market by Dosage Form:

3D Printed Tablets
3D Printed Capsules
3D Printed Multi Drug Implants
3D Printed Nanoparticles
3D Printed Solutions
Other 3D Printed Drug Dosage Forms

3D Printed Drugs Market by Technology:

Inkjet 3D Printed Drugs
Direct Write 3D Printed Drugs
Zip Dose 3D Printed Drugs
Thermal Inkjet 3D Printed Drugs
3D Printed Drugs based on Fused Deposition Modeling
Powder Bed 3D Printed Drugs
Stereo Lithography (SLA) 3D Printed Drugs
Semi Solid Extrusion (SSE) 3D Printed Drugs

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Matched content

Editor’s pick